Cambridge, Massachusetts, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s ...
We changed the address of the Stockhouse website from www.stockhouse.com to stockhouse.com. When this page refreshes you will be logged in with the new address ...
Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) ...
(RTTNews) - ProMIS Neurosciences (PMN) announced the FDA has granted Fast Track designation to PMN310, the company's lead therapeutic candidate in development for the treatment of Alzheimers disease.
CAMBRIDGE, Massachusetts, March 11, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results